[评估⁹⁹ᵐTc-MIBI预测小细胞肺癌患者化疗反应的价值]

[Evaluation of 99mTc-MIBI to predict chemotherapeutic response in patients with small cell lung carcinoma].

作者信息

Yamamoto Y, Nishiyama Y, Kawasaki Y, Satoh K, Takashima H, Ohkawa M, Tanabe M

机构信息

Department of Radiology, Kagawa Medical University.

出版信息

Nihon Igaku Hoshasen Gakkai Zasshi. 1996 Nov;56(13):980-1.

PMID:8969063

Abstract

The purpose of this study was to evaluate the relationship between 99mTc-MIBI (MIBI) accumulation and the response to chemotherapy. Twelve patients with small cell lung carcinoma (SCLC) underwent MIBI SPECT before chemotherapy. SPECT data were acquired 15 minutes and 2 hours after the injection of 600MBq MIBI. The early ratio (ER), delayed ratio (DR) and retention index (RI) was measured. Tumor response were classified into complete remission (CR), partial remission (PR) and no change (NC) by follow-up CT examination. The mean +/- standard deviation of ER was 3.10 +/- 0.85 (n = 4) for CR, 2.72 +/- 0.46 (n = 5) for PR and 2.43 +/- 0.95 (n = 3) for NC. DR was 3.05 +/- 1.11 for CR, 2.64 +/- 0.30 for PR and 1.90 +/- 0.82 for NC. RI was -3.0 +/- 11.69 for CR, -1.84 +/- 11.03 for PR and -18.19 +/- 38.51 for NC. CR, DR and RI were not significantly correlated with tumor response (CR, PR, NC) MIBI has the potential to predict the response to chemotherapy in SCLC.

摘要

本研究的目的是评估99mTc-甲氧基异丁基异腈（MIBI）摄取与化疗反应之间的关系。12例小细胞肺癌（SCLC）患者在化疗前接受了MIBI单光子发射计算机断层扫描（SPECT）。在注射600MBq MIBI后15分钟和2小时采集SPECT数据。测量早期比值（ER）、延迟比值（DR）和滞留指数（RI）。通过随访CT检查将肿瘤反应分为完全缓解（CR）、部分缓解（PR）和无变化（NC）。CR组ER的平均值±标准差为3.10±0.85（n = 4），PR组为2.72±0.46（n = 5），NC组为2.43±0.95（n = 3）。CR组DR为3.05±1.11，PR组为2.64±0.30，NC组为1.90±0.82。CR组RI为-3.0±11.69，PR组为-1.84±11.03，NC组为-18.19±38.51。CR、DR和RI与肿瘤反应（CR、PR、NC）无显著相关性。MIBI有可能预测SCLC的化疗反应。